Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial. (2019)

First Author: Davies A
Attributed to:  Infrastructure for collaboration: Leeds MRC Medical Bioinformatics Centre funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/s1470-2045(18)30935-5

PubMed Identifier: 30948276

Publication URI: http://europepmc.org/abstract/MED/30948276

Type: Journal Article/Review

Volume: 20

Parent Publication: The Lancet. Oncology

Issue: 5

ISSN: 1470-2045